Amgen
Search results
At Regeneron, we've been committed to making a difference in patients' lives for over 30 years. We've done this by following the science. One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.
Discover how Regeneron helps people with serious diseases by exploring our FDA-approved medicines, industrial operations, investigational pipeline and more.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life ...
Find the latest Regeneron Pharmaceuticals, Inc. (REGN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Get the latest Regeneron Pharmaceuticals Inc (REGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Jul 30, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab). The authorization now includes post-exposure prophylaxis in people at high risk for progression ...
Regeneron | 464,834 followers on LinkedIn. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network...
Mar 23, 2021 · Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to EUA. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase ...
